Aerie Pharmaceuticals, Inc. (AERI)

18.83 -0.14 (-0.74%) At close: 4:00PM EDT

Aerie Pharmaceuticals, Inc.

4301 Emperor Boulevard
Suite 400
Durham, NC 27703
United States
919 237 5300
http://www.aeriepharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 365

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Vicente J. Anido Jr.	CEO & Chairman	1.13M	N/A	1953
Mr. Thomas A. Mitro	Pres & COO	582.78k	N/A	1958
Dr. Casey C. Kopczynski	Co-Founder & Chief Scientific Officer	582.51k	2.2M	1961
Mr. Richard James Rubino CPA	CFO, Sec. & Treasurer	620.37k	N/A	1958
Mr. John W. LaRocca Esq.	Gen. Counsel & Assistant Sec.	576.3k	N/A	1966
Mr. Jeffrey Calabrese	Director of Accounting	N/A	N/A	N/A
Ms. Ami Bavishi	Director of Investor Relations	N/A	N/A	N/A
Andrew Allen	Chief Compliance Officer	N/A	N/A	N/A
Mr. Tad Heitmann	Head of Communications	N/A	N/A	N/A
Evan Hockman	VP of Sales	N/A	N/A	N/A

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is also developing AR-15512 to treat signs and symptoms of dry eye; and AR-1105, AR-13503 SR, and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina.

Corporate Governance

Aerie Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2021 is 8. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.